Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) – Equities researchers at Piper Jaffray Companies issued their Q3 2018 earnings per share (EPS) estimates for Spring Bank Pharmaceuticals in a report released on Tuesday, August 14th. Piper Jaffray Companies analyst E. Tenthoff anticipates that the company will earn ($0.54) per share for the quarter. Piper Jaffray Companies currently has a “Overweight” rating and a $25.00 target price on the stock. Piper Jaffray Companies also issued estimates for Spring Bank Pharmaceuticals’ Q4 2018 earnings at ($0.52) EPS, FY2018 earnings at ($1.82) EPS, Q1 2019 earnings at ($0.50) EPS, Q2 2019 earnings at ($0.54) EPS, Q3 2019 earnings at ($0.58) EPS, Q4 2019 earnings at ($0.65) EPS and FY2019 earnings at ($2.28) EPS.

Separately, Cantor Fitzgerald set a $35.00 price objective on Spring Bank Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, August 2nd. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Spring Bank Pharmaceuticals has an average rating of “Buy” and an average target price of $30.00.

SBPH opened at $11.50 on Thursday. The stock has a market cap of $158.62 million, a PE ratio of -6.15 and a beta of -0.12. Spring Bank Pharmaceuticals has a 52-week low of $10.81 and a 52-week high of $18.93.

Spring Bank Pharmaceuticals (NASDAQ:SBPH) last released its quarterly earnings results on Thursday, August 2nd. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.51) by $0.22.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. BVF Inc. IL lifted its position in shares of Spring Bank Pharmaceuticals by 1.1% during the 1st quarter. BVF Inc. IL now owns 832,247 shares of the company’s stock worth $12,800,000 after purchasing an additional 8,773 shares during the last quarter. BlackRock Inc. lifted its position in shares of Spring Bank Pharmaceuticals by 1,498.8% during the 2nd quarter. BlackRock Inc. now owns 483,258 shares of the company’s stock worth $5,727,000 after purchasing an additional 453,032 shares during the last quarter. Morse Asset Management Inc lifted its position in shares of Spring Bank Pharmaceuticals by 7.1% during the 2nd quarter. Morse Asset Management Inc now owns 177,500 shares of the company’s stock worth $2,103,000 after purchasing an additional 11,725 shares during the last quarter. Millennium Management LLC lifted its position in shares of Spring Bank Pharmaceuticals by 82.3% during the 1st quarter. Millennium Management LLC now owns 91,663 shares of the company’s stock worth $1,410,000 after purchasing an additional 41,372 shares during the last quarter. Finally, C WorldWide Group Holding A S lifted its position in shares of Spring Bank Pharmaceuticals by 4.9% during the 2nd quarter. C WorldWide Group Holding A S now owns 91,567 shares of the company’s stock worth $1,085,000 after purchasing an additional 4,245 shares during the last quarter. 29.41% of the stock is owned by institutional investors and hedge funds.

In other Spring Bank Pharmaceuticals news, insider Martin J. Driscoll acquired 4,000 shares of the business’s stock in a transaction that occurred on Monday, August 13th. The stock was acquired at an average price of $12.02 per share, with a total value of $48,080.00. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 15.60% of the stock is currently owned by insiders.

Spring Bank Pharmaceuticals Company Profile

Spring Bank Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapeutics using small molecule nucleic acid hybrid (SMNH) chemistry platform. The company's lead SMNH product candidate is inarigivir soproxil, for the treatment of chronic hepatitis B virus (HBV).

Featured Story: Fundamental Analysis

Earnings History and Estimates for Spring Bank Pharmaceuticals (NASDAQ:SBPH)

Receive News & Ratings for Spring Bank Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.